StandardStandard

Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover. / Njoku, Kelechi; Pierce, Andrew; Chiasserini, Davide et al.
Yn: eBioMedicine, Cyfrol 102, 04.2024, t. 105064.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Njoku, K, Pierce, A, Chiasserini, D, Geary, B, Campbell, AE, Kelsall, J, Reed, R, Geifman, N, Whetton, AD & Crosbie, EJ 2024, 'Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover', eBioMedicine, cyfrol. 102, tt. 105064. https://doi.org/10.1016/j.ebiom.2024.105064

APA

Njoku, K., Pierce, A., Chiasserini, D., Geary, B., Campbell, A. E., Kelsall, J., Reed, R., Geifman, N., Whetton, A. D., & Crosbie, E. J. (2024). Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover. eBioMedicine, 102, 105064. https://doi.org/10.1016/j.ebiom.2024.105064

CBE

Njoku K, Pierce A, Chiasserini D, Geary B, Campbell AE, Kelsall J, Reed R, Geifman N, Whetton AD, Crosbie EJ. 2024. Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover. eBioMedicine. 102:105064. https://doi.org/10.1016/j.ebiom.2024.105064

MLA

VancouverVancouver

Njoku K, Pierce A, Chiasserini D, Geary B, Campbell AE, Kelsall J et al. Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover. eBioMedicine. 2024 Ebr;102:105064. Epub 2024 Ebr 20. doi: 10.1016/j.ebiom.2024.105064

Author

RIS

TY - JOUR

T1 - Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: Leveraging proteomics and machine learning for biomarker discover

AU - Njoku, Kelechi

AU - Pierce, Andrew

AU - Chiasserini, Davide

AU - Geary, Bethany

AU - Campbell, Amy E.

AU - Kelsall, Janet

AU - Reed, Rachel

AU - Geifman, Nophar

AU - Whetton, Anthony D.

AU - Crosbie, Emma J.

N1 - Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2024/4

Y1 - 2024/4

N2 - BACKGROUND: The anatomical continuity between the uterine cavity and the lower genital tract allows for the exploitation of uterine-derived biomaterial in cervico-vaginal fluid for endometrial cancer detection based on non-invasive sampling methodologies. Plasma is an attractive biofluid for cancer detection due to its simplicity and ease of collection. In this biomarker discovery study, we aimed to identify proteomic signatures that accurately discriminate endometrial cancer from controls in cervico-vaginal fluid and blood plasma.METHODS: Blood plasma and Delphi Screener-collected cervico-vaginal fluid samples were acquired from symptomatic post-menopausal women with (n = 53) and without (n = 65) endometrial cancer. Digitised proteomic maps were derived for each sample using sequential window acquisition of all theoretical mass spectra (SWATH-MS). Machine learning was employed to identify the most discriminatory proteins. The best diagnostic model was determined based on accuracy and model parsimony.FINDINGS: A protein signature derived from cervico-vaginal fluid more accurately discriminated cancer from control samples than one derived from plasma. A 5-biomarker panel of cervico-vaginal fluid derived proteins (HPT, LG3BP, FGA, LY6D and IGHM) predicted endometrial cancer with an AUC of 0.95 (0.91-0.98), sensitivity of 91% (83%-98%), and specificity of 86% (78%-95%). By contrast, a 3-marker panel of plasma proteins (APOD, PSMA7 and HPT) predicted endometrial cancer with an AUC of 0.87 (0.81-0.93), sensitivity of 75% (64%-86%), and specificity of 84% (75%-93%). The parsimonious model AUC values for detection of stage I endometrial cancer in cervico-vaginal fluid and blood plasma were 0.92 (0.87-0.97) and 0.88 (0.82-0.95) respectively.INTERPRETATION: Here, we leveraged the natural shed of endometrial tumours to potentially develop an innovative approach to endometrial cancer detection. We show proof of principle that endometrial cancers secrete unique protein signatures that can enable cancer detection via cervico-vaginal fluid assays. Confirmation in a larger independent cohort is warranted.FUNDING: Cancer Research UK, Blood Cancer UK, National Institute for Health Research.

AB - BACKGROUND: The anatomical continuity between the uterine cavity and the lower genital tract allows for the exploitation of uterine-derived biomaterial in cervico-vaginal fluid for endometrial cancer detection based on non-invasive sampling methodologies. Plasma is an attractive biofluid for cancer detection due to its simplicity and ease of collection. In this biomarker discovery study, we aimed to identify proteomic signatures that accurately discriminate endometrial cancer from controls in cervico-vaginal fluid and blood plasma.METHODS: Blood plasma and Delphi Screener-collected cervico-vaginal fluid samples were acquired from symptomatic post-menopausal women with (n = 53) and without (n = 65) endometrial cancer. Digitised proteomic maps were derived for each sample using sequential window acquisition of all theoretical mass spectra (SWATH-MS). Machine learning was employed to identify the most discriminatory proteins. The best diagnostic model was determined based on accuracy and model parsimony.FINDINGS: A protein signature derived from cervico-vaginal fluid more accurately discriminated cancer from control samples than one derived from plasma. A 5-biomarker panel of cervico-vaginal fluid derived proteins (HPT, LG3BP, FGA, LY6D and IGHM) predicted endometrial cancer with an AUC of 0.95 (0.91-0.98), sensitivity of 91% (83%-98%), and specificity of 86% (78%-95%). By contrast, a 3-marker panel of plasma proteins (APOD, PSMA7 and HPT) predicted endometrial cancer with an AUC of 0.87 (0.81-0.93), sensitivity of 75% (64%-86%), and specificity of 84% (75%-93%). The parsimonious model AUC values for detection of stage I endometrial cancer in cervico-vaginal fluid and blood plasma were 0.92 (0.87-0.97) and 0.88 (0.82-0.95) respectively.INTERPRETATION: Here, we leveraged the natural shed of endometrial tumours to potentially develop an innovative approach to endometrial cancer detection. We show proof of principle that endometrial cancers secrete unique protein signatures that can enable cancer detection via cervico-vaginal fluid assays. Confirmation in a larger independent cohort is warranted.FUNDING: Cancer Research UK, Blood Cancer UK, National Institute for Health Research.

KW - Biomarker

KW - Cervico-vaginal fluid

KW - Endometrial cancer

KW - Plasma

KW - Proteins

U2 - 10.1016/j.ebiom.2024.105064

DO - 10.1016/j.ebiom.2024.105064

M3 - Article

C2 - 38513301

VL - 102

SP - 105064

JO - eBioMedicine

JF - eBioMedicine

ER -